Stayble Therapeutics
A clinical stage pharmaceutical company developing the injection treatment for disc-related chronic low back pain.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (89 %) | (80 %) | 1220 % | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (15333 %) | (1377 %) | - | - | (8576 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Stayble Therapeutics is a pioneering biotech company focused on developing innovative treatments for discogenic chronic low back pain (cLBP). Operating in the medical and healthcare market, Stayble Therapeutics targets patients who suffer from disabling back pain that is not adequately addressed by conventional therapies such as analgesics, physiotherapy, or spinal surgery. The company's core product, STA363, is a unique single injection procedure designed to stabilize the spinal disc by transforming it into connective tissue, thereby addressing the root cause of the pain rather than just the symptoms. This approach offers a faster and potentially permanent solution compared to existing surgical interventions.
Stayble Therapeutics primarily serves patients with discogenic cLBP, a condition that affects a significant portion of the population and imposes substantial costs on healthcare systems. The business model is centered around the development, clinical testing, and eventual commercialization of STA363. Revenue generation is expected to come from the sale of this proprietary treatment once it receives regulatory approval and enters the market.
The company is currently in the clinical phase 2b trial stage, aiming to bridge the gap between conservative and radical therapies for cLBP. By offering a less invasive and more effective treatment option, Stayble Therapeutics aims to improve the quality of life for millions of patients while reducing the economic burden on healthcare systems.
Keywords: discogenic, chronic low back pain, STA363, single injection, connective tissue, biotech, clinical trials, healthcare, pain management, innovative treatment.